Samsung is bringing a new heart health capability to select Galaxy smartwatches: an LVSD detection tool designed to flag early signs of Left Ventricular Systolic Dysfunction. LVSD is a condition where the heart’s left ventricle doesn’t pump effectively and is linked to around half of all heart failure cases. Catching subtle indicators early can prompt timely medical follow-ups, which may improve outcomes.
Built on the smartwatch’s existing electrocardiogram functionality used for tracking heart rate and blood pressure, the feature uses an AI algorithm developed with Korean medical device company Medical AI. The model was trained on data from more than 120,000 patients across hospitals in Korea. It has received clearance from the country’s Ministry of Food and Drug Safety, making the Galaxy Watch the first smartwatch platform to offer a certified LVSD detection tool there.
The feature will roll out initially in Korea on two models: Galaxy Watch8 and Galaxy Watch Ultra. The company has not confirmed a release timeline for other regions such as North America or Europe.
What this means for users:
– Proactive screening: The tool aims to surface early warning signs of LVSD from ECG readings, encouraging users to seek professional evaluation sooner.
– AI-powered insights: Training on a large clinical dataset helps the system recognize patterns associated with potential ventricular dysfunction.
– Certified in Korea: Regulatory approval in its home market supports clinical credibility for this use case on compatible devices.
Important notes:
– This feature is intended for detection support and does not diagnose heart disease. Users should consult a healthcare professional for medical advice and treatment decisions.
– While the company suggests early detection could reduce mortality risk, it has not provided supporting outcome data.
If you own a Galaxy Watch8 or Galaxy Watch Ultra in Korea, keep an eye out for a software update enabling LVSD detection. For users in other regions, availability will depend on local regulatory approvals.
